PT2907521T - Mutantes prongf inovadores e utilizações dos mesmos na produção de beta-ngf - Google Patents

Mutantes prongf inovadores e utilizações dos mesmos na produção de beta-ngf

Info

Publication number: PT2907521T
Authority: PT; Portugal
Prior art keywords: ngf; beta; production; prongf mutants; novel
Prior art date: 2011-12-19

Application number

PT151573201T

Other languages

English (en)

Inventor

Kathmann Daniela

Parthier Antje

Lorey Susan

Janowski Bernhard

Pultke Heiko

Anton Andreas

Original Assignee

Wacker Chemie Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-19

Filing date

2012-12-19

Publication date

2018-02-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47428641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2907521(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-19 Application filed by Wacker Chemie Ag filed Critical Wacker Chemie Ag

2018-02-22 Publication of PT2907521T publication Critical patent/PT2907521T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Ophthalmology & Optometry (AREA)
Analytical Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT151573201T 2011-12-19 2012-12-19 Mutantes prongf inovadores e utilizações dos mesmos na produção de beta-ngf PT2907521T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP11194208		2011-12-19

Publications (1)

Publication Number	Publication Date
PT2907521T true PT2907521T (pt)	2018-02-22

Family

ID=47428641

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT128056959T PT2672984E (pt)	2011-12-19	2012-12-19	Novos mutantes de prongf e suas utilizações na produção de beta-ngf
PT151573201T PT2907521T (pt)	2011-12-19	2012-12-19	Mutantes prongf inovadores e utilizações dos mesmos na produção de beta-ngf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT128056959T PT2672984E (pt)	2011-12-19	2012-12-19	Novos mutantes de prongf e suas utilizações na produção de beta-ngf

Country Status (27)

Country	Link
US (3)	US9617322B2 (pt)
EP (2)	EP2907521B1 (pt)
JP (4)	JP6039146B2 (pt)
KR (2)	KR101837802B1 (pt)
CN (2)	CN109400693A (pt)
AU (1)	AU2012357052B2 (pt)
BR (1)	BR112014014913B1 (pt)
CA (1)	CA2859262C (pt)
CY (2)	CY1117016T1 (pt)
DK (2)	DK2907521T3 (pt)
EA (1)	EA031333B1 (pt)
ES (2)	ES2545701T3 (pt)
HR (2)	HRP20150900T1 (pt)
HU (2)	HUE036265T2 (pt)
IL (1)	IL233137A0 (pt)
LT (1)	LT2907521T (pt)
MX (2)	MX370861B (pt)
NO (1)	NO2907521T3 (pt)
PL (2)	PL2672984T3 (pt)
PT (2)	PT2672984E (pt)
RS (2)	RS54220B1 (pt)
SG (2)	SG11201402585PA (pt)
SI (2)	SI2672984T1 (pt)
SM (2)	SMT201800097T1 (pt)
TR (1)	TR201802360T4 (pt)
WO (1)	WO2013092776A1 (pt)
ZA (1)	ZA201403753B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2907521B1 (en)	2011-12-19	2017-11-22	Wacker Chemie AG	Novel prongf mutants and uses thereof in the production of beta-ngf
US20160220639A1 (en) *	2013-09-11	2016-08-04	New York University	Methods and compositions for treating bone diseases
EP3406259A1 (en)	2017-05-24	2018-11-28	Dompé farmaceutici S.p.A.	Neurotrophins for use in the treatment of hearing loss
CN108456681B (zh) *	2018-03-26	2019-10-11	江苏中新医药有限公司	高效表达重组人神经生长因子的基因组合
US12378293B2 (en)	2018-04-27	2025-08-05	Chiesi Farmaceutici Spa	Production of nerve growth factor (NGF) and of muteins thereof
CA3102755A1 (en) *	2018-06-29	2020-01-02	The Doshisha	Formulation containing emricasan
JP2022502359A (ja)	2018-09-17	2022-01-11	キエージ・フアルマチエウテイチ・エツセ・ピ・ア	皮膚科障害の処置のための薬剤
IT201900014646A1 (it) *	2019-08-12	2021-02-12	Consiglio Nazionale Ricerche	Peptide neurotrofico resistente alle proteasi per il trattamento terapeutico di patologie neurodegenerative e/o cutanee
PT4031117T (pt) *	2019-09-17	2024-10-25	Chiesi Farm Spa	Mutante do ngf para utilização no tratamento ou prevenção de distúrbios oftálmicos
IL302317A (en)	2020-10-28	2023-06-01	Dompe Farm Spa	Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4039269A1 (en)	2021-02-05	2022-08-10	Dompe' Farmaceutici S.P.A.	Ngf isoform for use in the treatment of ocular pathologies
WO2022221351A1 (en)	2021-04-13	2022-10-20	Dompé Farmaceutici S.P.A.	Treatment of neuropathic corneal pain with ngf
EP4311554A1 (en)	2022-07-29	2024-01-31	Dompé farmaceutici S.p.a.	Combination for use in ophthalmology
EP4316505A1 (en)	2022-08-05	2024-02-07	Dompé farmaceutici S.p.a.	Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP4342485A1 (en)	2022-09-23	2024-03-27	Dompe' Farmaceutici S.P.A.	Ngf for the treatment of spasticity
EP4497431A1 (en)	2023-07-27	2025-01-29	Dompé farmaceutici S.p.A.	Pharmaceutical formulation comprising nerve growth factor
EP4623927A1 (en)	2024-03-27	2025-10-01	Dompe' Farmaceutici SpA	Ngf for use in the prevention or treatment of motor impairment caused by neonatal hypoxic-ischemic encephalopathy
EP4659759A1 (en)	2024-06-04	2025-12-10	Dompé farmaceutici SpA	Administration of ngf for the treatment of niemann-pick type c disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4139000A1 (de) *	1991-11-27	1993-06-03	Boehringer Mannheim Gmbh	Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
CA2265743A1 (en) *	1996-09-13	1998-03-19	Advanced Medicine Research Institute	Ophthalmic composition of neurotrophic factor, optic nerve functional disorder-treating agent and method for treating optic nerve functional disorder
ES2213861T3 (es)	1998-10-09	2004-09-01	Scil Proteins Gmbh	Procedimiento de obtencion de ngf-beta activa.
US20030040082A1 (en)	2001-02-16	2003-02-27	Mark Tuszynski	Mutant pro-neurotrophin with improved activity
ATE554784T1 (de)	2001-05-25	2012-05-15	Cornell Res Foundation Inc	Hochaffiner ligand für p75 neurotrophin-rezeptor
DE10360483B4 (de)	2003-12-22	2007-11-15	Scil Proteins Gmbh	Expressionsvektor und dessen Verwendung
US20080286323A1 (en) *	2004-01-19	2008-11-20	Nsgene A/S	Human Therapeutic Cells Secreting Nerve Growth Factor
US20080050776A1 (en) *	2006-05-26	2008-02-28	Kenneth Neet	Stable mutated pro nerve growth factors
CN101260398B (zh) *	2007-03-07	2013-06-05	舒泰神（北京）生物制药股份有限公司	神经生长因子基因定位改造动物及其制备方法和应用
EP2907521B1 (en)	2011-12-19	2017-11-22	Wacker Chemie AG	Novel prongf mutants and uses thereof in the production of beta-ngf

2012
- 2012-12-19 EP EP15157320.1A patent/EP2907521B1/en active Active
- 2012-12-19 CN CN201711352074.1A patent/CN109400693A/zh active Pending
- 2012-12-19 WO PCT/EP2012/076251 patent/WO2013092776A1/en not_active Ceased
- 2012-12-19 HU HUE15157320A patent/HUE036265T2/hu unknown
- 2012-12-19 AU AU2012357052A patent/AU2012357052B2/en active Active
- 2012-12-19 PT PT128056959T patent/PT2672984E/pt unknown
- 2012-12-19 TR TR2018/02360T patent/TR201802360T4/tr unknown
- 2012-12-19 LT LTEP15157320.1T patent/LT2907521T/lt unknown
- 2012-12-19 SI SI201230289T patent/SI2672984T1/sl unknown
- 2012-12-19 HU HUE12805695A patent/HUE027245T2/en unknown
- 2012-12-19 DK DK15157320.1T patent/DK2907521T3/en active
- 2012-12-19 DK DK12805695.9T patent/DK2672984T3/en active
- 2012-12-19 SM SM20180097T patent/SMT201800097T1/it unknown
- 2012-12-19 ES ES12805695.9T patent/ES2545701T3/es active Active
- 2012-12-19 RS RS20150561A patent/RS54220B1/sr unknown
- 2012-12-19 SG SG11201402585PA patent/SG11201402585PA/en unknown
- 2012-12-19 MX MX2017012894A patent/MX370861B/es unknown
- 2012-12-19 KR KR1020147019162A patent/KR101837802B1/ko active Active
- 2012-12-19 KR KR1020167027254A patent/KR20160120788A/ko not_active Withdrawn
- 2012-12-19 ES ES15157320.1T patent/ES2657344T3/es active Active
- 2012-12-19 EP EP12805695.9A patent/EP2672984B1/en active Active
- 2012-12-19 BR BR112014014913-5A patent/BR112014014913B1/pt active IP Right Grant
- 2012-12-19 HR HRP20150900TT patent/HRP20150900T1/hr unknown
- 2012-12-19 RS RS20180159A patent/RS56893B1/sr unknown
- 2012-12-19 US US14/366,460 patent/US9617322B2/en active Active
- 2012-12-19 EA EA201491155A patent/EA031333B1/ru unknown
- 2012-12-19 SI SI201231212T patent/SI2907521T1/en unknown
- 2012-12-19 CA CA2859262A patent/CA2859262C/en active Active
- 2012-12-19 PL PL12805695T patent/PL2672984T3/pl unknown
- 2012-12-19 MX MX2014007317A patent/MX353074B/es active IP Right Grant
- 2012-12-19 CN CN201280062855.6A patent/CN104203264B/zh active Active
- 2012-12-19 JP JP2014546588A patent/JP6039146B2/ja active Active
- 2012-12-19 PL PL15157320T patent/PL2907521T3/pl unknown
- 2012-12-19 PT PT151573201T patent/PT2907521T/pt unknown
- 2012-12-19 SG SG10201605028VA patent/SG10201605028VA/en unknown
- 2012-12-19 NO NO15157320A patent/NO2907521T3/no unknown
2014
- 2014-05-22 ZA ZA2014/03753A patent/ZA201403753B/en unknown
- 2014-06-15 IL IL233137A patent/IL233137A0/en active IP Right Grant
2015
- 2015-08-20 SM SM201500201T patent/SMT201500201B/xx unknown
- 2015-08-26 CY CY20151100747T patent/CY1117016T1/el unknown
- 2015-12-22 US US14/978,407 patent/US10308694B2/en active Active
2016
- 2016-11-03 JP JP2016215749A patent/JP6622683B2/ja active Active
2018
- 2018-02-21 HR HRP20180307TT patent/HRP20180307T1/hr unknown
- 2018-02-21 CY CY20181100195T patent/CY1119926T1/el unknown
- 2018-08-07 JP JP2018148261A patent/JP2019011330A/ja active Pending
- 2018-08-08 JP JP2018148957A patent/JP2019006781A/ja active Pending
2019
- 2019-04-05 US US16/376,969 patent/US20200031893A1/en active Pending

Also Published As

Publication number	Publication date
HRP20180307T1 (hr)	2018-03-23
EP2672984B1 (en)	2015-05-27
HK1202055A1 (en)	2015-09-18
CN109400693A (zh)	2019-03-01
MX353074B (es)	2017-12-19
KR20140103318A (ko)	2014-08-26
HUE027245T2 (en)	2016-10-28
EP2672984A1 (en)	2013-12-18
SMT201500201B (it)	2015-10-30
US20150087020A1 (en)	2015-03-26
CN104203264B (zh)	2018-08-28
HRP20150900T1 (hr)	2015-10-09
DK2907521T3 (en)	2018-03-05
MX2014007317A (es)	2014-11-25
EP2907521B1 (en)	2017-11-22
ES2545701T3 (es)	2015-09-15
CN104203264A (zh)	2014-12-10
SMT201800097T1 (it)	2018-03-08
JP6622683B2 (ja)	2019-12-18
PL2907521T3 (pl)	2018-04-30
LT2907521T (lt)	2018-05-10
PT2672984E (pt)	2015-10-01
AU2012357052B2 (en)	2015-06-25
BR112014014913B1 (pt)	2020-12-01
EA031333B1 (ru)	2018-12-28
NO2907521T3 (pt)	2018-04-21
NZ627054A (en)	2015-06-26
SG10201605028VA (en)	2016-07-28
US10308694B2 (en)	2019-06-04
CA2859262A1 (en)	2013-06-27
PL2672984T3 (pl)	2015-10-30
JP2015501828A (ja)	2015-01-19
HUE036265T2 (hu)	2018-06-28
BR112014014913A2 (pt)	2017-06-13
CY1119926T1 (el)	2018-12-12
JP6039146B2 (ja)	2016-12-07
ES2657344T3 (es)	2018-03-02
IL233137A0 (en)	2014-07-31
KR101837802B1 (ko)	2018-03-12
RS56893B1 (sr)	2018-04-30
WO2013092776A1 (en)	2013-06-27
MX370861B (es)	2020-01-08
JP2019006781A (ja)	2019-01-17
JP2019011330A (ja)	2019-01-24
RS54220B1 (sr)	2015-12-31
US9617322B2 (en)	2017-04-11
SI2672984T1 (sl)	2015-11-30
US20200031893A1 (en)	2020-01-30
TR201802360T4 (tr)	2018-03-21
SG11201402585PA (en)	2014-10-30
CA2859262C (en)	2021-04-06
EA201491155A1 (ru)	2015-01-30
CY1117016T1 (el)	2017-04-05
JP2017071611A (ja)	2017-04-13
DK2672984T3 (en)	2015-08-24
US20160244496A1 (en)	2016-08-25
AU2012357052A1 (en)	2014-07-24
SI2907521T1 (en)	2018-03-30
ZA201403753B (en)	2015-11-25
KR20160120788A (ko)	2016-10-18
EP2907521A1 (en)	2015-08-19

Publication	Publication Date	Title
HRP20180307T1 (hr)	2018-03-23	Novi mutanti prongf-a i njihova upotreba u proizvodnji beta-ngf-a
GB2488918B (en)	2014-03-05	Sugar mixtures and methods for production and use thereof
SG10201608870UA (en)	2016-12-29	Nanostructured articles and methods to make the same
SG11201404580QA (en)	2014-10-30	Nanostructured materials and methods of making the same
SG11201404488UA (en)	2014-08-28	Nanostructured materials and methods of making the same
PL2766682T3 (pl)	2017-03-31	Sposób, linia technologiczna i wykorzystanie linii technologicznej do wytwarzania cząstek liofilizowanych
IL230650A (en)	2016-12-29	Methylphenidate-drug-mediators and processes for their preparation and use
HUE042637T2 (hu)	2019-07-29	Laminátumok és azok elõállítására szolgáló módszerek
EP2652141A4 (en)	2014-05-14	MICROORGANISMS AND METHOD FOR PRODUCING 1,4-CYCLOHEXANDIMETHANOL
SG11201405941QA (en)	2014-10-30	Article and method of making the same
EP2697378A4 (en)	2014-10-01	IDENTIFICATION AND USE OF KRP MUTANTS IN PLANTS
EP2791075A4 (en)	2015-10-28	SYNTHETIC MARBLE HIGH HARDENING AND METHOD OF MANUFACTURING THEREOF
ZA201400558B (en)	2015-08-26	Methods for the production of a cosmetic composition comprising leukolectin and uses thereof
SI2710043T1 (sl)	2016-08-31	Morskemu psu-podoben hondroitin sulfat in postopek za njegovo pripravo
EP2649217A4 (en)	2014-11-26	ARTICLE AND METHOD FOR ITS MANUFACTURE AND USE
EP2654486A4 (en)	2015-01-07	STRUCTURED SURFACE WITH SEVERAL COLUMNS AND CAPS AND METHOD FOR THE PRODUCTION THEREOF
SI2864087T1 (sl)	2017-01-31	Lesni kompozitni material z aerogeli in ustrezni proizvodni postopek ter uporaba
IL233354A0 (en)	2014-08-31	2, 6-Dihalo-5-Alkoxy-4-converted-pyrimidines, pyrimidine-carbaldehydes, and methods of production and use
IL226234B (en)	2018-07-31	Nucleons, ribocapsids and methods for their production
ZA201308457B (en)	2015-02-25	Shark-like chondroitin sulphate and process for the preparation thereof
PL387453A1 (pl)	2010-09-13	Meble korkowe oraz sposób wytwarzania mebli korkowych
GB201016060D0 (en)	2010-11-10	Improvements in the measurement and control of process parameters
GB201215557D0 (en)	2012-10-17	Improvements in the manufacture of tiles